Samani N J, Cumin F, Kelly M, Wood J M
Department of Medicine, University of Leicester, United Kingdom.
Am J Physiol. 1994 Oct;267(4 Pt 1):E612-9. doi: 10.1152/ajpendo.1994.267.4.E612.
To assess the effects of inhibition of the renin-angiotensin system at different levels on plasma concentrations of components of the system and on renin and angiotensinogen gene expression, marmosets on a low-sodium diet were treated for 1 wk by continuous intraperitoneal infusion with either the renin inhibitor CGP-29287, the ACE inhibitor benazeprilat, the angiotensin II antagonist valsartan, the renin inhibitory monoclonal antibody R-3-36-16, or vehicle. Plasma total immunoreactive renin increased (14- to 20-fold) after all three modes of interference. Plasma angiotensinogen was significantly reduced in the benazeprilat- and valsartan-treated marmosets but not in the CGP-29287-treated animals. Plasma concentration of angiotensin II was significantly decreased in the benazeprilat-, CGP-29287-, and R-3-36-16-treated marmosets and was increased in the valsartan-treated marmosets. Kidney renin mRNA level increased 8- to 15-fold in all groups. Hepatic angiotensinogen mRNA level increased with CGP-29287 treatment but decreased with the other treatments. Kidney angiotensinogen mRNA level was not affected by any treatment. Different modes of inhibition of the renin-angiotensin system have different effects on plasma components of the system and liver angiotensinogen expression.
为评估不同水平抑制肾素-血管紧张素系统对该系统各组分血浆浓度以及肾素和血管紧张素原基因表达的影响,对低钠饮食的狨猴连续腹腔内输注肾素抑制剂CGP-29287、血管紧张素转换酶(ACE)抑制剂苯那普利拉、血管紧张素II拮抗剂缬沙坦、肾素抑制性单克隆抗体R-3-36-16或溶媒,治疗1周。在所有三种干预方式后,血浆总免疫反应性肾素均升高(14至20倍)。苯那普利拉和缬沙坦治疗的狨猴血浆血管紧张素原显著降低,但CGP-29287治疗的动物未降低。苯那普利拉、CGP-29287和R-3-36-16治疗的狨猴血浆血管紧张素II浓度显著降低,而缬沙坦治疗的狨猴血浆血管紧张素II浓度升高。所有组的肾脏肾素mRNA水平均升高8至15倍。肝血管紧张素原mRNA水平在CGP-29287治疗时升高,但在其他治疗时降低。肾脏血管紧张素原mRNA水平不受任何治疗的影响。不同方式抑制肾素-血管紧张素系统对该系统的血浆组分以及肝脏血管紧张素原表达有不同影响。